"Numerous studies support influenza vaccination of persons with egg allergy using modest precautions.
Evidence continues to mount

that there is cross-talk between skin barrier defects and immune responses in patients with atopic dermatitis. "

 

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2012
J Allergy Clin Immunol. 2013 Jan;131(1):55-66. doi: 10.1016/j.jaci.2012.11.007. Epub 2012 Nov 27.


http://www.ncbi.nlm.nih.gov/pubmed/23199604

.

Eczema & Shedding Vaccine Virus

A letter to friends and family-

 

 

 

 

Take no offense- But this is why I do not want my child around the vaccinated for 21-28 days- My child has eczema. Which was caused by her vaccines!

 

1)No child with atopic eczema or other skin disorder should be vaccinated.

 

2) No child should be vaccinated if any member of his family has eczema or other skin disorder.

 

3) Parents of children with eczema should be notified at the onset of the disease of the danger from vaccination contact.

 

4) If a sibling of a child with atopic eczema is vaccinated, he must be completely separated from that child for at least 21 days.

 

5) Forms used by state and local health departments for parents' consent to vaccination should include an appropriate warning of the contraindications.

6) Eczema vaccinatum should be a reportable disease.

 

7) Patients recently vaccinated must be excluded from pediatric wards containing patients with atopic eczema, other diseases of the skin, burns or healing surgical incisions.

 

INFO FROM THIS STUDY ON THE RIGHT
http://pediatrics.aappublications.org/content/22/2/259



Its 21-28 days because vaccines actually shed for 28+ days, meaning the vaccinated are contagious. 21-28 days is usually the end of shedding but we also know the immunocompromised become reservoirs of infection for lifelong shedding. Keep in mind all vaccines shed, not only live virus vaccines - I say this because the FDA has already said vaccines have unknown viruses that may cause tumors, that are hard to detect and may become ACTIVE during vaccine manufacturing.
 

 

"In some cases the cell lines (aborted fetal cells) that are used might be tumorigenic, that is, they form tumors when injected into rodents. Some of these tumor-forming cell lines may contain cancer-causing viruses that are not actively reproducing. Such viruses are hard to detect using standard methods. These latent, or "quiet," viruses pose a potential threat, since they might become active under vaccine manufacturing conditions.”

http://www.fda.gov/biologicsbloodvaccines/scienceresearch/biologicsresearchareas/ucm127327.htm

 


WOULD YOU RISK THIS ON YOUR CHILD???

 

This site below has an EXCELLENT way to explain shedding but I have also included proof that vaccines shed and make the vaccinated contagious with the studies below this link.

 

http://insidevaccines.com/wordpress/2008/02/24/secondary-transmission-%ef%bb%bfthe-short-and-sweet-about-live-virus-vaccine-shedding/

Vaccines SPREAD DISEASE/SHED to immuno-compromised children and the elderly and pregnant mothers.

This is a real risk no one ever thinks matters. Those vaccine viruses are just as contagious as a wild type viruses in the vaccinated. No matter what they say, those vaccine viruses shed to immunocompromised children and even the unborn. And youre sitting their saying please get vaccinated and shed to my immunocompromised child! It’s a no brainer. Shedding viruses cause DISEASE too! A virus doesnt discriminate even if its "weakened" it can still seroconvert to wild type virus!

 

"Excretion of small amounts of the live attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination."

 

http://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf

 

"A 12-month-old healthy boy had approximately 30 vesicular skin lesions 24 days after receiving varicella vaccine. Sixteen days later his pregnant mother had 100 lesions. Varicella-vaccine virus was identified by ...polymerase chain reaction in the vesicular lesions of the mother. After an elective abortion, no virus was detected in the fetal tissue. This case documents transmission of varicella-vaccine virus from a healthy 12-month-old infant to his pregnant mother."

 

http://www.ncbi.nlm.nih.gov/pubmed/9255208

 

"Twelve days after receiving an investigational Oka strain live attenuated varicella vaccine, a 38-year-old healthy white woman developed a rash consisting of 30 scattered lesions. Sixteen days later, her 2 children also developed rash. Swabs obtained from the skin lesions of the vaccinee and her children demonstrated the presence of varicella-zoster virus (VZV) DNA by a polymerase chain reaction (PCR) assay. Restriction endonuclease polymorphisms present in wild and vaccine type VZV were examined, and the amplified VZV DNA was determined to be vaccine type. This case documents transmission of varicella vaccine type virus from a healthy vaccinee to susceptible household contacts. Since vaccine-associated rashes are uncommon and mild, it is likely that transmission of vaccine virus will also be uncommon. With widespread immunization beginning in the United States, ongoing studies will define the frequency of this transmission."

http://www.ncbi.nlm.nih.gov/pubmed/9333170



"Excretion of small amounts of the live attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination."

 

http://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf



"Vaccine-type rotavirus was detected in all 50 antigen-positive specimens and 8 of 8 antigen-negative specimens. Nine (75%) of 12 EIA-positive and 1 EIA-negative samples tested culture-positive for vaccine-type rotavirus. Fecal shedding of rotavirus vaccine virus after the first dose of RV5 occurred over a wide range of post-vaccination days not previously studied."
 

http://www.ncbi.nlm.nih.gov/pubmed/21477676


“The FluMist influenza vaccine strains replicate in the nasopharynx and can be recovered and cultured from respiratory secretions of vaccinated individuals (shed). The pattern and duration of shedding is important to understand because with prolonged shedding at high titer there is a theoretical risk of loss of attenuated phenotype, reassortment with wild-type influenza virus during influenza season, and transmission of vaccine virus to unvaccinated people, some of whom may be immunocompromised and/or at risk for complications of live viral infections. “

“additional shedding samples collected every 7 days ... though some individuals shed vaccine strain virus as late as day 28”

 

www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM259175.pdf

 

“The RotaTeq vaccine contains five live, attenuated strains derived through laboratory reassortment of human rotavirus strains with a bovine rotavirus strain [3,4]. Three RotaTeq strains (WI78-8, BrB-9 and WI79-4) each contain a single human rotavirus gene segment and ten bovine rotavirus segments, and two strains (WI79-9 and SC2-9) contain two human strain segments and nine bovine strain segments. In the study, RotaTeq was detected in 16 stool samples. Ten of these contained between one and four individual vaccine component strains. Six samples were found to contain a vaccine-derived G1P[8] (vdG1P[8]) strain. vdG1P[8] is believed to be the product of a genetic reassortment event in which the G1 gene segment of strain WI79-9 is inserted into strain WI79-4, as evidenced by the association of G1-VP7 and P[8]-VP4 human rotavirus genes with the M2-VP3 and I2-VP6 of the bovine rotavirus. Donato et al. observed that approximately a fifth of the infants having diarrhea {DUH aka ROTAVIRUS} within 2 weeks of rotavirus vaccination were shedding vaccine strain components exclusive of any detectable enteric pathogen.”

http://www.ncbi.nlm.nih.gov/pubmed/23249230     FULL TEXT http://www.expert-reviews.com/doi/full/10.1586/erv.12.114

 

"Analysis of 36 individuals over age 60 years who were immunized with Zostavax revealed varicella zoster virus DNA in swabs of skin inoculation sites obtained immediately after immunization in 18 (50%) of 36 subjects and in saliva collected over 28 days in 21 (58%) of 36 subjects. Genotypic analysis of DNA extracted from 9 random saliva samples identified vaccine virus in ALL instances. In some immunized individuals over age 60, vaccine virus DNA is shed in saliva up to 4 weeks."

"Zostavax contains live attenuated VZV, and the package insert warns newly vaccinated individuals to avoid contact for an unspecified time with newborn infants, immunosuppressed individuals, and pregnant women who have not had chicken pox or have not been immunized for chicken pox. Because VZV DNA is present in saliva of zoster patients for at least 2 weeks [5] and VZV in saliva can also be infectious [6], we examined the inoculation site and saliva of Zostavax-vaccinated subjects for the presence of VZV DNA for 4 weeks after immunization"

 

FULL TEXT http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096786/ 

“During July 2005, the infant had multiple medical visits for respiratory illness and was hospitalized at a community hospital (hospital 1) for bronchiolitis and bacterial conjunctivitis. During August, she had medical visits for failure to thrive, fever, diarrhea, and anemia. Beginning 22 August 2005, she was hospitalized continuously at a regional medical center(hospital2),a children’s hospital (hospital 3), and a university hospital (hospital 4) for fever, irritability, bloody diarrhea, and recurrent infections. She never had paralysis. A stool specimen, obtained on 27 August 2005 on admission to hospital 3, was positive for an enterovirus that was ultimately confirmed to be a VACCINE DERIVED POLIO VIRUS by the Minnesota Department of Health Public Health Laboratory on 29 September 2005.”

http://www.ncbi.nlm.nih.gov/pubmed/19090774 

"A 44-year-old woman with long-standing common variable immunodeficiency who was receiving intravenous immune globulin suddenly had paralysis of all four limbs and the respiratory muscles, resulting in death. Type 2 VACCINE-derived poliovirus was isolated from stool."


http://www.nejm.org/doi/full/10.1056/NEJMoa1008677

Persistence of vaccine-derived polio viruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis.

Patient 1 was a 17-month-old girl. She had exhibited antibody deficiency and thus received inactivated polio vaccine (IPV). She was a household contact of a healthy OPV-vaccinated sibling. Limited data indicated that paralysis became evident in June 1995. All 3 fecal specimens collected 3–6 days after onset of paralysis yielded VACCINE-DERIVED POLIO VIRUS type 2. Recombination with the Sabin 1 strain was detected, with a crossover site at nt 5355 (3A). The girl died 8 days after onset of paralysis with obscured etiology.

Patient 2 was a boy born in January 2005. He received 4 doses of OPV, administered at birth and at 2, 4, and 6 months of age. In August 2005, he was hospitalized with irritability, drowsiness, hypotonia, and right paraparesis. Two collected fecal specimens tested were positive for VACCINE-DERIVED POLIO VIRUS type 2. Recombination with the Sabin 1 strain was also found at nt 5358. At baseline, he had mild anemia, hypogammaglobulinemia, and diminished CD4+ T-cell counts. A test result for HIV was negative. The expression of human leukocyte antigen DR on his lymphocytes was low, indicating major histocompatibility complex class II deficiency. His condition deteriorated during the next several months, with involvement of respiratory muscles and 3 episodes of aspiration pneumonia. He died of respiratory failure at 11 months of age. Follow-up fecal cultures during his illness showed persistent VACCINE-DERIVED POLIO VIRUS type 2 shedding (11).


Patient 3 was a boy born in January 2006. Beginning at 2 months of age, he had chronic diarrhea, malabsorption, and failure to thrive. Recurrent episodes of pneumonia also developed, beginning when the boy was 4 months of age. OPV was administered at birth and at 2, 4, and 6 months of age. In October 2006, he was referred to hospital showing symptoms of acute paralysis of the left leg of 2 weeks’ duration, followed by involvement of his right leg and upper arms, accompanied by drowsiness, fever, and hypotonia. Laboratory results showed lymphopenia; anemia; decreased levels of immunoglobulin (Ig) G, IgA, and IgM; and diminished CD3+, CD4+, and CD8+ T-cell counts (Table 2). VACCINE-DERIVED POLIO VIRUS type 2 was isolated from both of his collected fecal specimens. The final diagnosis was severe combined immunodeficiency (SCID) caused by RAG2 mutation (R229W) (N. Parvaneh, unpub. data). The boy died <3 months after onset of paralysis after gram-negative sepsis in January 2007.

Patient 4 was a 15-month-old boy who had fever and weakness of the lower limbs in December 2006. He received 4 doses of OPV, administered at birth and at 2, 4, and 6 months of age. At admission to the hospital, his right leg was completely flaccid, and the left was paretic. VACCINE-DERIVED POLIO VIRUS type 3 was isolated from his feces. Recombination with the Sabin 1 strain was detected at the 3Dpol region of the genome. Immunologic workup showed hypogammaglobulinemia and diminished CD19+ B lymphocytes. The final diagnosis was X-linked agammaglobulinemia. The patient was treated with intravenous Ig and physical therapy. Follow-up fecal cultures showed no virus. He died 11 months after onset of paralysis with chronic respiratory insufficiency (12,13).

Patient 5, a girl born in September 2006, was the third child of healthy parents. She received OPV at birth and in November 2006. In February 2007, she was hospitalized with severe pneumonia and paraparesis. Two fecal specimens collected on days 3 and 5 after onset of paralysis were positive for VACCINE-DERIVED POLIO VIRUS types 1 and 2. B cell–negative T cell–negative SCID was diagnosed (Table 2); the girl died of severe sepsis and multiple organ failure in April 2007, 1 month after onset of VAPP. Patient 6, a boy 2 years of age, had weakness in his right leg. At 7 months of age, progressive paralysis of the extremity developed after a febrile illness. His first fecal specimen was positive for the Sabin 2 strain. He subsequently experienced several episodes of pneumonia and upper respiratory infections necessitating hospitalization. Immunologic workup favored a diagnosis of X-linked agammaglobulinemia (Table 2). Electrodiagnostic studies of the affected limb indicated femoral nerve mononeuropathy. One of 2 additional fecal specimens collected was positive for VACCINE-DERIVED POLIO VIRUS type 2. The boy began intravenous Ig substitution (600 mg/kg every 4 weeks, continuing to date). Follow-up fecal samples became negative for polioviruses. His immunodeficiency is under control, and he has only residual paralysis of the right leg.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321898/ OR http://wwwnc.cdc.gov/eid/article/16/7/09-1606_article.htm

ACCESSED JULY 2013

“Type 1 vaccine-derived poliovirus (VDPV) was identified in September 2005, from an unvaccinated Amish infant hospitalized in Minnesota with severe combined immunodeficiency. An investigation was conducted to determine the source of the virus and its means of transmission."

http://www.ncbi.nlm.nih.gov/pubmed/19090774

“All of the OPV-like isolates and the 'suspected' iVDPVs carried mutations at specific positions in their partially sequenced regions, which have been associated with reversion of the attenuated Sabin PV vaccine strains to INCREASED neurovirulence.” CONCLUSIONS: Thus, this study adds further evidence to the observation that immunodeficient individuals may excrete OPV strains with potential neurovirulent phenotypes.” "Prolonged excretion of Polio Viruses by immunodeficient individuals is of major concern, because continued replication of Polio Viruses in the human gut could result in the reversion of these viruses to GREATER NEUROVIRULENCE. When exposed to OPV, immunodeficient patients may become chronically infected, spreading potentially neurovirulent VDPVs for many months or years to close contacts and children who are no longer being vaccinated after termination of OPV vaccination in the near future."

http://www.ncbi.nlm.nih.gov/pubmed/17105568

“the Vaccine Derived Polio Virus was found in an area where conditions favor Vaccine Derived Polio Virus emergence and spread.”

http://www.ncbi.nlm.nih.gov/pubmed/17449127


"OBJECTIVES: To evaluate the threat of vaccine-derived poliovirus (1-15% divergence from the respective Sabin strain) for a poliomyelitis-free population in a country with a long-standing routine vaccination program. CONCLUSIONS: Our findings, which show that OPV is excreted for a significant period by children with high humoral immunity, emphasize the long-term potential threat from Vaccine Derived Polio Virus in highly vaccinated populations. "

http://www.ncbi.nlm.nih.gov/pubmed/16805227

 

Not only shedding vaccine viruses MADE for the vaccine, but THERE ARE OTHER UNINTENDED VIRUSES IN VACCINES that arent detected or tested for from transmission of animal and human cell lines.
 

Investigations of porcine circovirus type 1 (PCV1) in vaccine-related and other cell lines. “Porcine circovirus type 1 (PCV1) is highly prevalent in swine and was recently reported in some rotavirus vaccines.” 011 Oct 26;29(46):8429-37. Epub 2011 Aug 9

 

http://www.ncbi.nlm.nih.gov/pubmed/21835219?dopt=Abstract



ABORTED FETAL CELL LINES- "In some cases the cell lines that are used might be tumorigenic, that is, they form tumors when injected into rodents. Some of these tumor-forming cell lines may contain cancer-causing viruses that are not actively reproducing. Such viruses are hard to detect using standard methods. These latent, or "quiet," viruses pose a potential threat, since they might become active under vaccine manufacturing conditions.
WOULD YOU RISK THIS ON YOUR CHILD????!!! Well, I am NOT.
 

http://www.fda.gov/biologicsbloodvaccines/scienceresearch/biologicsresearchareas/ucm127327.htm



'Xenotropic murine leukemia virus-related virus (XMRV) is a recently discovered human retrovirus that has been found in both chronic fatigue syndrome & prostate cancer patients. There is a potential safety concern regarding XMRV in cell substrates used in vaccines...'

 

http://www.fda.gov/biologicsbloodvaccines/scienceresearch/biologicsresearchareas/ucm127327.htm

"The use of tumorigenic and tumor-derived cells is a major safety concern due to the potential presence of viruses such as retroviruses and oncogenic (CANCER) DNA viruses that could be associated with tumorigencity (formation of tumors), Therefore, detection of persistent, latent (quiet) DNA viruses, and endogenous RETROVIRUSES (ex. AIDS is a slow replicating retrovirus) in vaccine cell substrates is important for vaccine safety, particularly in the development of live viral vaccines, where there are no or minimal virus inactivation and removal steps during vaccine manufacturing."

 

http://www.fda.gov/biologicsbloodvaccines/scienceresearch/biologicsresearchareas/ucm127327.htm
 

 

“ Additionally, a baboon endogenous virus strain M7 was detected, likely due to the monkey cell line in which RotaTeq was produced from.”“ The sample of RotaTeq vaccine tested positive for rotavirus A and baboon endogenous virus, as previously reported by Victoria and colleagues [17]. The origin of the baboon endogenous virus is assumed to be related to the African green monkey-derived Vero cell line used in its manufacture and cross-hybridization of its endogenous retroviruses to the baboon endogenous retrovirus probes [17].

 

Microarray analysis did not detect PCV from the RotaTeq vaccine, which confirmed the previous results from Victoria et al. that LLMDA detected PCV from Rotarix but did not detect PCV from the RotaTeq vaccine [17]. However, PCV2 in RotaTeq vaccine was detected by PCR assays. RotaTeq contained small PCV-1 and PCV-2 genome fragments but did not contain detectable larger portions of PCV genomes [30]. Studies have shown that the amount of PCV in RotaTeq was about 4000 times lower than the PCV in Rotarix, with the PCV in RotaTeq being barely detectable [25, 31, 32]. A case study by Ranucci et al. has reported that the concentration of PCV-2 DNA fragment in clinical consistency lots was in the range of below limit of detection to 6.4 × 103 copies/mL when measured by QPCR, and that PCV1 was below limit of detection (0.1–0.8 × 103 copies/mL) [30]. ” 2014

 

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980782/

 

 


"A five-year-old girl, vaccinated against varicella-zoster virus (VZV) presented with clinical symptoms of herpes zoster in the 6th cervical dermatome. A VZV direct immune-fluorescence assay was negative three times but additional genotypical analysis showed a VZV strain genotype 2 (Oka vaccine strain). Therefore the diagnosis of a breakthrough varicella disease with the vaccine strain was established. An immunodeficiency was ruled out and the patient responded well to the initiated therapy. This case demonstrates that a negative VZV direct immunofluorescence assay does not exclude an infection with the vaccine strain." 2013

http://www.ncbi.nlm.nih.gov/pubmed/23358727


"A 23-year-old teacher presented to hospital with a mild case of varicella. VZV vaccine strain vOka that resembles Varilrix but not Varivax or Biken strains was isolated from the skin lesion of the patient and was identified by single nucleotide polymorphism (SNP) analysis. The teacher denied having varicella vaccine before. Retrospective analysis suggests the transmission came from a pupil who developed zoster 13 months after varicella vaccine Varilrix."

http://www.ncbi.nlm.nih.gov/pubmed/21134454



"A 25-day-old infant developed varicella 22 days after her mother received varicella vaccine postpartum. Infection with vaccine-strain varicella-zoster virus was confirmed by genetic analysis. The mother had no postvaccination rash nor did other contacts have rash or recent vaccination." 2012

http://www.ncbi.nlm.nih.gov/pubmed/22572750


"Viral concentration was low in serum and urine but remarkably higher in the throat swab................."
"Even though live attenuated measles vaccines have been used for more than 40 years, data are scarce on the extent to which vaccine virus replicates in or is shed by vaccinees (5). Isolation of infectious vaccine virus from the blood and pharynx of vaccinated children by propagation on canine renal cell culture was successfully performed in early studies with the Edmonston strain (9), from experimentally vaccinated Cynomolgus monkeys after vaccination with the Schwarz vaccine strain (10), and in a study evaluating fever and rash appearing 3 to 9 days after measles vaccination (11)." 2013

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697452/

 

 

"A 12-year-old boy developed a skin rash following administration of MMR varicella zoster virus vaccine [route, dosage and outcome not stated].

The boy's medical history included DiGeorge syndrome and juvenile idiopathic arthritis, which was treated with etanercept. He inadvertently received the MMR varicella zoster virus vaccine during a well-child visit. Ten days later, he was hospitalised with a 2-day history of fever, conjunctivitis, rash and sore throat. His mother held further doses of etanercept. Upon admission, physical examination revealed a blanching morbilliform rash on his face, ears, neck, chest, back and limbs. He also had mild conjunctivitis, palatal petechiae with posterior pharyngeal erythema and mild post auricular cervical lymphadenopathy.

The boy began receiving aciclovir. Urine and skin samples were positive for measles virus, and were phylogenetically clustered as genotype A with Edmonston reference strain. He was diagnosed with vaccine-associated disease."  2014

 

http://www.ncbi.nlm.nih.gov/pubmed/24346604

-Pediatric Infectious Disease Journal 33: 117, No. 1, Jan 2014 - USA
http://link.springer.com/article/10.1007/s40278-014-0119-z

 


“An outbreak of nine cases of mumps was reported from a total of 97 vaccinated nursing students at two medical colleges in Thailand in 2010, 16-26 days after administration of MMR vaccine containing the L-Zagreb mumps strain......This study provides another virologically confirmed example of mumps resulting from the L-Zagreb vaccine strain.” 2013

http://www.ncbi.nlm.nih.gov/pubmed/23089079